December 04, 2022

Dr. John Boone on how Izotropic’s CT technology will outperform mammography for more accurate breast cancer detection

“We believe, based upon our computer simulation, that breast CT system will outperform mammography, for instance for a 4 mm lesion, a pretty small tumor, by the order of 40%. We are very excited about the increase in cancer detection performance that breast CT will provide.” States Dr. John Boone, Principal Founder, Director of Izotropic Corporation (CSE: IZO) and the 2019 William D. Coolidge Award Recipient in an interview with InvestorIntel’s Peter Clausi.

Dr. Boone went on to explain that Izotropic’s breast CT technology is comfortable for patients as it does not involve painful breast compression and produces true 3-D images of breasts at very high resolution. Dr. Boone added that the technology has the potential to substantially reduce false-negative or false-positive breast biopsies thereby reducing the stress on the patient and also reducing the cost for the medical system.

To access the complete interview, click here

Disclaimer: Izotropic Corporation is an advertorial member of InvestorIntel Corp.

Disclaimer: The author of this post may or may not be a shareholder of any of the companies mentioned in this column. None of the companies discussed in the above feature have paid for this content. The writer of this article/post/column/opinion is not an investment advisor, and is neither licensed to nor is making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence. To access the InvestorIntel.com disclaimer and other important legal notices, click here.

Leave a Reply

Your email address will not be published. Required fields are marked *